Autologous Bone Marrow-Derived Stem Cells for Treating Diabetic Neuropathy in Metabolic Syndrome.

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
hyperinsulinemia 1 endocrinologydiseases
type 2 diabetes mellitus 3 endocrinologydiseases
diabetes mellitus 13 endocrinologydiseases
diabetic autonomic neuropathy 1 endocrinologydiseases
diabetic neuropathy 24 endocrinologydiseases
hyperglycemia 2 endocrinologydiseases
complications of diabetes mellitus 1 endocrinologydiseases
metabolic syndrome 2 endocrinologydiseases
type 1 diabetes mellitus 2 endocrinologydiseases

There are not enough annotations found in this document to create the proximity graph.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
Select Disease Character Offset Disease Term Instance
complications of diabetes mellitus 873 /2017Publication date (epub): 10/2017AbstractDiabetic neuropathy is one of the most common and serious complications of diabetes mellitus and metabolic syndrome. The current therapy strategies, including glucose control and pain management,
diabetes mellitus 890 date (epub): 10/2017AbstractDiabetic neuropathy is one of the most common and serious complications of diabetes mellitus and metabolic syndrome. The current therapy strategies, including glucose control and pain management,
diabetes mellitus 2037 diabetic neuropathy.1. IntroductionDiabetic neuropathy is one of the most frequent complications in diabetes mellitus and metabolic syndromes, which cause high rate of disability and mortality [[1], [2]]. Diabetic neuropathy
diabetes mellitus 2534 neuropathy [[4]]. However, it showed a marginal effect on preventing diabetic neuropathy in type 2 diabetes mellitus , indicating that other factors might be also involved in the nerve injury in these patients [[4]]. The
diabetes mellitus 3774 profile of diabetic neuropathy and BMC therapy. Finally, some solutions to restore BMC function in diabetes mellitus are addressed.2. Current Clinical Management of Diabetic NeuropathyDiabetic neuropathy has been defined
diabetes mellitus 4120 other causes, which is the most common complication of diabetes, affecting 30–50% of individuals with diabetes mellitus . Patients with diabetic neuropathy have poor quality of life and reduced work productivity, along with
diabetes mellitus 5172 the regeneration capacity in nerve is limited, causing the irreversible neuropathy in patients with diabetes mellitus . Several therapeutics, such as aldose reductase inhibitor and α-lipoic acid, have been developed based
diabetes mellitus 5677 novel therapeutics in future.The high quality clinical evidence from 17 randomized studies (7 in type 1 diabetes mellitus , 8 in type 2 diabetes mellitus, and 2 in both types) showed that strict glucose control significantly
diabetes mellitus 5708 high quality clinical evidence from 17 randomized studies (7 in type 1 diabetes mellitus, 8 in type 2 diabetes mellitus , and 2 in both types) showed that strict glucose control significantly prevented the development of
diabetes mellitus 5870 glucose control significantly prevented the development of diabetic neuropathy in patients with type 1 diabetes mellitus [[12]]. In contrast, the strict glucose control could reduce the incidence of neuropathy in type 2 diabetes
diabetes mellitus 5987 [[12]]. In contrast, the strict glucose control could reduce the incidence of neuropathy in type 2 diabetes mellitus , but without statistical significance (P = 0.06). However, the benefit from the aggressive glucose control
diabetes mellitus 6583 present in the patients with peripheral diabetic neuropathy [[13]]. Microvascular insufficiency in diabetes mellitus may also contribute to the pathogenetic mechanism in nerve neuropathy. The adequate blood supply from
diabetes mellitus 6845 normal structure and function in nerves. The strict blood glucose control is applied in patients with diabetes mellitus [[4]]. Poor glycemic control is clearly associated with the development of diabetic neuropathy. In addition,
diabetes mellitus 13945 result in the defective mobilization of BMSCs [[47]]. In a clinical trial (NCT01102699), patients with diabetes mellitus showed impaired mobilization ability of HSCs and EPCs while being in response to G-CSF [[48]]. In another
diabetic autonomic neuropathy 13806 stimulate the release of BMCs into bloodstream [[46]]. Recent report demonstrated that the occurrence of diabetic autonomic neuropathy might result in the defective mobilization of BMSCs [[47]]. In a clinical trial (NCT01102699), patients
diabetic neuropathy 1223 deficiency of local neurotrophic and angiogenic factors contribute significantly to the pathologies of diabetic neuropathy . Experimental and clinical studies have shown that bone marrow-derived stem cells (BMCs) therapy represents
diabetic neuropathy 1541 cytokines, which has a potential to inhibit inflammation and promote angiogenesis and neurotrophy in diabetic neuropathy . In this review, we discuss the clinical practice in diabetic neuropathy and the therapeutic effect
diabetic neuropathy 1614 angiogenesis and neurotrophy in diabetic neuropathy. In this review, we discuss the clinical practice in diabetic neuropathy and the therapeutic effect of BMC. We subsequently illustrate the functional impairment of autologous
diabetic neuropathy 1785 illustrate the functional impairment of autologous BMCs due to the interrupted bone marrow niche in diabetic neuropathy . We anticipate that the functional restoration of BMCs could improve their therapeutic effect and enable
diabetic neuropathy 1937 functional restoration of BMCs could improve their therapeutic effect and enable their wide applications in diabetic neuropathy .1. IntroductionDiabetic neuropathy is one of the most frequent complications in diabetes mellitus and
diabetic neuropathy 2504 reduce the incidence of diabetes neuropathy [[4]]. However, it showed a marginal effect on preventing diabetic neuropathy in type 2 diabetes mellitus, indicating that other factors might be also involved in the nerve injury
diabetic neuropathy 2866 therapy response in the progressive stage of diabetes neuropathy [[5]]. Recently, it is speculated that diabetic neuropathy is secondary to the deficiency of local growth factors, besides which, a number of inflammatory mediators,
diabetic neuropathy 3065 of inflammatory mediators, such as interleukins and chemokines, are involved in the progression of diabetic neuropathy [[6]]. There is a growing interest in the scientific community for cellular therapies, such as utilizing
diabetic neuropathy 3328 and its complications [[7]]. In the past decade, BMCs have been applied as a promising therapy for diabetic neuropathy because of their multipotency and their comprehensive paracrine secretion of anti-inflammatory cytokines,
diabetic neuropathy 3686 autologous BMCs, yielding their modest therapy efficacy [[9]]. Here, we review the clinical profile of diabetic neuropathy and BMC therapy. Finally, some solutions to restore BMC function in diabetes mellitus are addressed.2.
diabetic neuropathy 4153 common complication of diabetes, affecting 30–50% of individuals with diabetes mellitus. Patients with diabetic neuropathy have poor quality of life and reduced work productivity, along with high healthcare costs. Cardiac autonomic
diabetic neuropathy 5826 and 2 in both types) showed that strict glucose control significantly prevented the development of diabetic neuropathy in patients with type 1 diabetes mellitus [[12]]. In contrast, the strict glucose control could reduce
diabetic neuropathy 6524 found that blood serum autoimmune antibodies were significantly present in the patients with peripheral diabetic neuropathy [[13]]. Microvascular insufficiency in diabetes mellitus may also contribute to the pathogenetic mechanism
diabetic neuropathy 6938 patients with diabetes mellitus [[4]]. Poor glycemic control is clearly associated with the development of diabetic neuropathy . In addition, it has been found that diabetes could reduce neurotrophic factors in peripheral nerves
diabetic neuropathy 10164 Therapy for Diabetic NeuropathyIt has been found that growth factor therapy is an attractive option for diabetic neuropathy [[35]]. The administration of growth factors can promote angiogenesis and neural regeneration. Some
diabetic neuropathy 10783 double-blinded trial in humans showed that VEGF could evoke statistically significant symptomatic improvement of diabetic neuropathy [[36]]. Other growth factors, such as insulin-like growth factor (IGF), nerve growth factor (NGF), and
diabetic neuropathy 10987 factor (NGF), and ciliary neurotrophic factor, were also investigated in experimental animals with diabetic neuropathy [[37]]. They were found to ameliorate development of neuropathy and improve nerve function. Therefore,
diabetic neuropathy 11214 therapeutic strategy to promote angiogenesis and neuron regeneration may be promising in treatment of diabetic neuropathy .In this context, BMCs, which can produce multiple angiogenic and neurotrophic growth factors and potentially
diabetic neuropathy 11551 factor therapy [[38]]. Currently, preclinical studies showed their potential therapeutic effects in diabetic neuropathy . One of the advantages to use BMCs is the possibility of autograft; that is, they can be harvested from
diabetic neuropathy 12644 endogenous cell mobilization is an alternative to cell transplantation therapy. In a rodent model with diabetic neuropathy , intraperitoneal administration of granulocyte colony-stimulating factor (G-CSF) recruited stem cells
diabetic neuropathy 14660 cardiovascular disease related to cardiac autonomic neuropathy. Collectively, these reports indicate that diabetic neuropathy may adversely affect stem cell-based therapies in patients with diabetic neuropathy.6. Functional Restoration
diabetic neuropathy 14744 reports indicate that diabetic neuropathy may adversely affect stem cell-based therapies in patients with diabetic neuropathy .6. Functional Restoration of BMCsTo improve BMC mobilization in diabetes, some types of cytokines could
diabetic neuropathy 17061 clinical trials, the potential to translate this therapeutic strategy into a pilot clinical trial for diabetic neuropathy is very promising. However, several steps still need to be completed before that can be a reality. Firstly,
diabetic neuropathy 17601 and other strategies. In conclusion, BMC therapy may become a potential therapeutic option to treat diabetic neuropathy .Figure 1Schematic of bone marrow niche. Bone marrow niche is anatomical compartments constituted by
hyperglycemia 2359 autonomic nervous system [[3]]. However, its pathophysiology is not yet fully elucidated. The treatment of hyperglycemia is a recommended strategy to reduce the incidence of diabetes neuropathy [[4]]. However, it showed a
hyperglycemia 4705 complicated (Figure 1). Diabetes mellitus often cause several prolonged metabolic disorders, including hyperglycemia , hyperinsulinemia, growth factor abnormalities, and dyslipidemia. These disorders could bring a complicated
hyperinsulinemia 4720 (Figure 1). Diabetes mellitus often cause several prolonged metabolic disorders, including hyperglycemia, hyperinsulinemia , growth factor abnormalities, and dyslipidemia. These disorders could bring a complicated alternation,
metabolic syndrome 912 10/2017AbstractDiabetic neuropathy is one of the most common and serious complications of diabetes mellitus and metabolic syndrome . The current therapy strategies, including glucose control and pain management, are not effective for
metabolic syndrome 2059 IntroductionDiabetic neuropathy is one of the most frequent complications in diabetes mellitus and metabolic syndrome s, which cause high rate of disability and mortality [[1], [2]]. Diabetic neuropathy can affect a wide
type 1 diabetes mellitus 5670 develop novel therapeutics in future.The high quality clinical evidence from 17 randomized studies (7 in type 1 diabetes mellitus , 8 in type 2 diabetes mellitus, and 2 in both types) showed that strict glucose control significantly
type 1 diabetes mellitus 5863 strict glucose control significantly prevented the development of diabetic neuropathy in patients with type 1 diabetes mellitus [[12]]. In contrast, the strict glucose control could reduce the incidence of neuropathy in type 2 diabetes
type 2 diabetes mellitus 2527 diabetes neuropathy [[4]]. However, it showed a marginal effect on preventing diabetic neuropathy in type 2 diabetes mellitus , indicating that other factors might be also involved in the nerve injury in these patients [[4]]. The
type 2 diabetes mellitus 5701 future.The high quality clinical evidence from 17 randomized studies (7 in type 1 diabetes mellitus, 8 in type 2 diabetes mellitus , and 2 in both types) showed that strict glucose control significantly prevented the development of
type 2 diabetes mellitus 5980 mellitus [[12]]. In contrast, the strict glucose control could reduce the incidence of neuropathy in type 2 diabetes mellitus , but without statistical significance (P = 0.06). However, the benefit from the aggressive glucose control

You must be authorized to submit a review.